Zobrazeno 1 - 10
of 23
pro vyhledávání: '"D R Camidge"'
Autor:
T. L. Peters, T. Patil, A. T. Le, K. D. Davies, P. M. Brzeskiewicz, H. Nijmeh, L. Bao, D. R. Camidge, D. L. Aisner, R. C. Doebele
Publikováno v:
npj Precision Oncology, Vol 5, Iss 1, Pp 1-6 (2021)
Abstract EGFR mutant non-small cell lung cancer patients' disease demonstrates remarkable responses to EGFR-targeted therapy, but inevitably they succumb to acquired resistance, which can be complex and difficult to treat. Analyzing acquired resistan
Externí odkaz:
https://doaj.org/article/a60d71a2c6b74878abf284abc023a3a1
Autor:
D. R. Camidge, L. Bao, P. M. Brzeskiewicz, Hala Nijmeh, Kurtis D. Davies, Anh T. Le, Dara L. Aisner, Tejas Patil, Robert C. Doebele, T. L. Peters
Publikováno v:
NPJ Precision Oncology
npj Precision Oncology, Vol 5, Iss 1, Pp 1-6 (2021)
npj Precision Oncology, Vol 5, Iss 1, Pp 1-6 (2021)
EGFR mutant non-small cell lung cancer patients' disease demonstrates remarkable responses to EGFR-targeted therapy, but inevitably they succumb to acquired resistance, which can be complex and difficult to treat. Analyzing acquired resistance throug
Publikováno v:
British Journal of Cancer
Sharrocks, K, Spicer, J, Camidge, D R & Papa, S 2014, ' The impact of socioeconomic : status on access to cancer clinical trials ', British Journal of Cancer, vol. 111, no. 9, pp. 1684-7 . https://doi.org/10.1038/bjc.2014.108
Sharrocks, K, Spicer, J, Camidge, D R & Papa, S 2014, ' The impact of socioeconomic : status on access to cancer clinical trials ', British Journal of Cancer, vol. 111, no. 9, pp. 1684-7 . https://doi.org/10.1038/bjc.2014.108
Cancer clinical trials enable the development of novel agents for the potential benefit of cancer patients. Enrolment in a trial offers patients the chance of superior efficacy coupled to the risk of unanticipated toxicity. For trial results to be ge
Autor:
Thomas W. Flaig, Wells A. Messersmith, D. R. Camidge, Colin D. Weekes, Harry A. Drabkin, Arvind Dasari, Sami Diab, Antonio Jimeno, Lia Gore, Karl D. Lewis
Publikováno v:
Investigational New Drugs. 31:115-125
Background This phase I study evaluated the safety, tolerability and preliminary efficacy of sorafenib combined with vorinostat in patients with solid tumors. Patients and methods Patients were treated with sorafenib 400 mg po bid daily and vorinosta
Publikováno v:
British Journal of Cancer
The risk of suicide in cancer patients has been reported as elevated in several countries. These patients are exposed to many medicines that may confuse or provide a means for harm, potentially also increasing their risk from accidents. Ratios of obs
Publikováno v:
British Journal of Cancer
ICD-9 code 163 (malignant neoplasm of pleura) listed as underlying cause of death detected only 40% of Scottish mesothelioma cases (all body sites) from the cancer registry in 1981–1999. This is lower than both the previously published 55% figure,
Autor:
D R Camidge, P J Laud, D Johnstone, A. Hughes, Jim Growcott, John R. Foster, K J Randall, Mike Pemberton
Publikováno v:
British Journal of Cancer
Easily accessible normal tissues expressing the same molecular site(s) of drug action as malignant tissue offer an enhanced potential for early proof of anticancer drug mechanism and estimation of the biologically effective dose. Studies were underta
Autor:
A R Soames, D R Camidge, P J Laud, A. Hughes, C J Sadler, K R Randall, Jayne Wright, Paul D. Smith, John R. Foster
Publikováno v:
British Journal of Cancer
We have demonstrated the feasibility of detecting and quantifying six cell-cycle-related nuclear markers (Ki67, pRb, p27, phospho-p27 (phosphorylated p27), phospho-pRb (phosphorylated pRb), phospho-HH3 (phosphorylated histone H3)) in plucked human sc
Publikováno v:
British Journal of Clinical Pharmacology. 56:613-619
Self-poisoning by ingestion or inhalation is common, and it is important to study its various epidemiological manifestations with clear definitions. Data on fatal self-poisonings are recorded nationally within the UK and are codified according to the
Autor:
D R Camidge
Publikováno v:
Journal of the Royal Society of Medicine. 94:567-572
Dysphagia occurs in only a small percentage of patients with lung cancer, but the frequency of this cancer means that large numbers are affected. Non-quantitative analysis of a large Scottish series of lung cancer cases indicates the following eight